Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.32 USD | -2.39% | -4.88% | +168.66% |
May. 10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
May. 09 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Vera Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Vera Therapeutics, Inc.
Wedbush | |
Oppenheimer | |
Raymond James | |
Cantor Fitzgerald | |
Jefferies & Co. | |
HC Wainwright | |
Guggenheim | |
JPMorgan Chase | |
Cowen | |
Evercore ISI |
EPS Revisions
- Stock Market
- Equities
- VERA Stock
- Consensus Vera Therapeutics, Inc.